-
Product Insights
Cutaneous Lupus Erythematosus – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous Lupus Erythematosus - Drugs In Development, 2023’, provides an overview of the Cutaneous Lupus Erythematosus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Drugs In Development, 2023’, provides an overview of the Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...
-
Product Insights
Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Drugs In Development, 2023’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Nivolumab + Relatlimab) in Metastatic Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Nivolumab + Relatlimab) in Metastatic Uveal Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Nivolumab + Relatlimab) in Metastatic Uveal Melanoma Drug Details:Nivolumab and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Levalbuterol Sulfate in Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levalbuterol Sulfate in Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Levalbuterol Sulfate in Chronic...
-
Company Profile
Cipher Pharmaceuticals Inc – Company Profile
Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company’s major products comprise actikerall, to treat slightly palpable and moderately thick hyperkeratotic actinic keratosis (grade I/II) of the face, forehead, and balding scalp; epuris, to treat severe nodular and inflammatory acne, acne con globate and recalcitrant acne; ozanex for the topical treatment of impetigo, vaniqa, to treat unwanted facial hair in women. its pipeline products include treprostinil sodium, to treat pulmonary arterial hypertension; MOB-015, to...
Add to Basket -
Product Insights
Net Present Value Model: Epuris
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Epuris Drug Details Isotretinoin (Absorica /...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – levalbuterol sulfate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry levalbuterol sulfate Drug Details Levalbuterol sulfate (ASF-1096) is under development for the treatment of...
-
Product Insights
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers...
-
Product Insights
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Global Clinical Trials Review, H1, 2017" provides an overview of Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers...